Assess skin lesions before and during therapy.
Assess for signs and symptoms of infection during or after a course of therapy. Discontinue alefacept if patient develops serious infection.
Assess for allergic reactions during therapy. Discontinue therapy if reaction occurs.
Discontinue alefacept if malignancy develops.
Assess for signs and symptoms of hepatic impairment during treatment. Discontinue alefacept if patient develops hepatic impairment.Lab Test Considerations
Monitor CD4 and T lymphocyte count before initiating and every 2 wks during therapy. Withhold alefacept if CD4 and T lymphocyte counts are below 250 cells/microliter and monitor weekly. Discontinue if counts remain below 250 cells/microliter for 1 mo.